Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy
Clinical Science2017Vol. 131(5), pp. 395–409
Citations Over TimeTop 10% of 2017 papers
Abstract
Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is an underdiagnosed and important type of cardiomyopathy and/or polyneuropathy that requires increased awareness within the medical community. Raising awareness among clinicians about this type of neuropathy and lethal form of heart disease is critical for improving earlier diagnosis and the identification of patients for treatment. The following review summarizes current criteria used to diagnose both hereditary and wild-type ATTR (ATTRwt) amyloidosis, tools available to clinicians to improve diagnostic accuracy, available and newly developing therapeutics, as well as a brief biochemical and biophysical background of TTR amyloidogenesis.
Related Papers
- → A new mutation causing familial amyloidotic polyneuropathy(1989)35 cited
- → An aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys 54(1999)21 cited
- Transthyretin (prealbumin) in familial amyloidotic polyneuropathy: genetic and functional aspects.(1988)
- → Evaluation of Serum Variant Prealbumin Levels, and its Behavior after Plasma Exchange for Familial Amyloidotic Polyneuropathy (Type 1)(1988)3 cited
- → DAYS ALIVE AND OUTSIDE OF HOSPITAL IS GREATER AMONG PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS COMPARED TO LIGHT CHAIN CARDIAC AMYLOIDOSIS AFTER INITIAL HOSPITALIZATION(2018)